TW202400639A - 5t4結合劑及其用途 - Google Patents

5t4結合劑及其用途 Download PDF

Info

Publication number
TW202400639A
TW202400639A TW112117412A TW112117412A TW202400639A TW 202400639 A TW202400639 A TW 202400639A TW 112117412 A TW112117412 A TW 112117412A TW 112117412 A TW112117412 A TW 112117412A TW 202400639 A TW202400639 A TW 202400639A
Authority
TW
Taiwan
Prior art keywords
seq
acid sequence
amino acid
antibody
cdr2
Prior art date
Application number
TW112117412A
Other languages
English (en)
Chinese (zh)
Inventor
波妮 漢默
傑佛瑞 Ｎ 希加基
希瑪 坎特克
查爾斯 凱佩蘭
Original Assignee
美商艾克塞里克斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾克塞里克斯公司 filed Critical 美商艾克塞里克斯公司
Publication of TW202400639A publication Critical patent/TW202400639A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112117412A 2022-05-13 2023-05-10 5t4結合劑及其用途 TW202400639A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263341944P 2022-05-13 2022-05-13
US63/341,944 2022-05-13

Publications (1)

Publication Number Publication Date
TW202400639A true TW202400639A (zh) 2024-01-01

Family

ID=88731098

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112117412A TW202400639A (zh) 2022-05-13 2023-05-10 5t4結合劑及其用途

Country Status (16)

Country Link
US (1) US20250326858A1 (enExample)
EP (1) EP4522660A4 (enExample)
JP (1) JP2025518493A (enExample)
KR (1) KR20250024530A (enExample)
CN (2) CN120607619A (enExample)
AU (1) AU2023267764A1 (enExample)
CA (1) CA3252305A1 (enExample)
CL (2) CL2024003442A1 (enExample)
CO (1) CO2024015383A2 (enExample)
CR (1) CR20240489A (enExample)
DO (1) DOP2024000234A (enExample)
IL (1) IL316788A (enExample)
MX (1) MX2024013871A (enExample)
PE (1) PE20251275A1 (enExample)
TW (1) TW202400639A (enExample)
WO (1) WO2023220626A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180472A1 (zh) * 2024-02-28 2025-09-04 惠和生物技术(上海)有限公司 单克隆抗体分子及其用途
US20260008868A1 (en) * 2024-07-05 2026-01-08 Solve Therapeutics, Inc. 5t4-binding proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596295A (en) * 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
CA2959694C (en) * 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
CN114025797A (zh) * 2019-05-31 2022-02-08 昆士兰医学研究所理事会 抗Gal9免疫抑制性结合分子

Also Published As

Publication number Publication date
EP4522660A2 (en) 2025-03-19
PE20251275A1 (es) 2025-05-14
WO2023220626A3 (en) 2023-12-14
IL316788A (en) 2025-01-01
CL2025002572A1 (es) 2025-10-03
CL2024003442A1 (es) 2025-02-28
WO2023220626A2 (en) 2023-11-16
KR20250024530A (ko) 2025-02-18
MX2024013871A (es) 2024-12-06
US20250326858A1 (en) 2025-10-23
AU2023267764A1 (en) 2024-11-21
CN119546643A (zh) 2025-02-28
CR20240489A (es) 2025-01-07
CN120607619A (zh) 2025-09-09
DOP2024000234A (es) 2025-02-28
JP2025518493A (ja) 2025-06-17
EP4522660A4 (en) 2026-04-29
CA3252305A1 (en) 2023-11-16
CO2024015383A2 (es) 2025-02-04

Similar Documents

Publication Publication Date Title
WO2021058000A1 (zh) 抗人Claudin18.2抗体及其应用
WO2017084495A1 (zh) Pd-l1抗体、其抗原结合片段及其医药用途
CN109069639B (zh) Gitr抗体、方法及用途
JP7840312B2 (ja) 多重特異性結合性作用剤およびその使用
US20250197502A1 (en) Multispecific binding agents and uses thereof
JP7627258B2 (ja) 抗ｂｃｍａ抗体、その抗原結合断片、及びそれらの医療用途
US20250326858A1 (en) 5t4 binding agents and uses thereof
JP2025000617A (ja) Ｔ細胞受容体のデルタ１鎖に特異的な抗体
US20230357391A1 (en) Cd47 binding agents and uses thereof
JP7854423B2 (ja) Ｐｄ－ｌ１結合性作用剤およびその使用
WO2023231705A1 (zh) 靶向SIRPα和PD-L1的双特异性抗体或其抗原结合片段及应用
CN118974098A (zh) 多重特异性结合剂及其用途
TW202511294A (zh) 介白素-13受體次單元α-2結合劑及其用途
TW202525855A (zh) Ｉｌｔ２結合劑及其用途
TW202221038A (zh) 抗ｔｒｏｐ－２抗體、其抗原結合片段或其突變體、及其醫藥用途